Kw-6356    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease6

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04342273
(ClinicalTrials.gov)
March 31, 20208/4/2020A Through QT/QTc Study of KW-6356A Through QT/QTc Study of KW-6356 in Japanese Healthy AdultsParkinson's DiseaseDrug: KW-6356;Drug: Placebo;Drug: MoxifloxacinKyowa Kirin Co., Ltd.NULLCompleted20 Years54 YearsAll128Phase 1Japan
2NCT04070495
(ClinicalTrials.gov)
August 27, 201926/8/2019A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinA Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)Parkinson's DiseaseDrug: KW-6356;Drug: Clarithromycin;Drug: RifampicinKyowa Kirin Co., Ltd.NULLCompleted20 Years44 YearsMale20Phase 1Japan
3NCT03970798
(ClinicalTrials.gov)
May 22, 201923/5/2019A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinA Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinParkinson's DiseaseDrug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356Kyowa Kirin Co., Ltd.NULLCompleted20 Years44 YearsMale50Phase 1Japan
4NCT03830528
(ClinicalTrials.gov)
February 26, 20193/2/2019A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsA Phase I Study of KW-6356 in Japanese and Caucasian Healthy AdultsParkinson's DiseaseDrug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: PlaceboKyowa Kirin Co., Ltd.NULLCompleted20 Years44 YearsMale48Phase 1Japan
5NCT03703570
(ClinicalTrials.gov)
September 29, 20185/10/2018A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsA Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing PreparationsParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Kirin Co., Ltd.NULLCompleted20 Years80 YearsAll502Phase 2Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02939391
(ClinicalTrials.gov)
September 201617/10/2016A Study of KW-6356 in Subjects With Early Parkinson's DiseaseAn Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's DiseaseParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Kirin Co., Ltd.NULLCompleted20 Years80 YearsAll175Phase 2Japan